<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>9580438</identifier>
<setSpec>1130-0108</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Nosti-Escanilla, M P</dc:author>
<dc:author>Pe√±a, A S</dc:author>
<dc:description xml:lang="en">The chronic inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are multifactorial pathologies. There is overwhelming evidence that genetic factors play a pivotal role in the predisposition to suffer from IBD. The severity of the inflammatory response depends on genes coding for proteins which regulate the cytokine production. Among them, NF kappa B stands out as the most important regulator of the gene expression of several pro- and anti-inflammatory genes. We present hereby its structure, function, regulation and the role played in IBD. Different theories relating the mechanism of action of glucocorticosteroids to NF kappa B are described in this review as well. The more accurate knowledge of the NF kappa B physiology has allowed new therapeutical approaches to inflammatory diseases to appear, namely the transfer to primary intestinal epithelial cells by an adenoviral vector of a mutant I kappa B (the inhibitory protein of NF kappa B) and the local use of p65 antisense phosphorothioate oligonucleotides.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1998 Feb </dc:date>
<dc:title xml:lang="es">NF kappa B y enfermedad inflamatoria intestinal.</dc:title>
<dc:title xml:lang="en">[NF-kappa B and inflammatory intestinal diseases].</dc:title>
<dc:publisher>Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva</dc:publisher>
</metadata>
</record>
</pubmed-document>
